Form 4: Elevation Oncology CEO Exercises Stock Options and Sells Shares
SEC Form 4 Filing
CEO Joseph J. Ferra Jr. exercised stock options and sold shares of Elevation Oncology, Inc. on February 15, 2025.
Summary
- On February 15, 2025, Joseph J. Ferra Jr., the CEO of Elevation Oncology, Inc., executed transactions involving the company's stock.
- Ferra exercised stock options to acquire 800,000 shares of common stock at a price of $0.6717 per share.
- He also disposed of 25,000 shares of common stock related to the vesting of restricted stock units (RSUs).
- Additionally, Ferra disposed of 9,211 shares to cover tax obligations at a price of $0.6717.
- Following these transactions, Ferra directly owns 125,271 shares of Elevation Oncology common stock and holds options for 800,000 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's common for executives to exercise stock options and sell a portion of the acquired shares to cover taxes and diversify their holdings.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and exercise prices are typical for the biotechnology industry, where long-term incentives are used to retain key personnel.
- Comparing Ferra's holdings and transactions to those of executives at similar-sized oncology companies (e.g., Relay Therapeutics, Black Diamond Therapeutics) could provide further context.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, potentially causing a slight dilution of equity.
- The vesting of RSUs and exercise of options are part of the CEO's compensation package, impacting employee morale and retention.
Key Dates
| Date | Description |
|---|---|
| 02/15/2025 | Date of earliest transaction: Exercise of stock options, disposal of shares due to RSU vesting and tax obligations. |
| 02/14/2035 | Expiration date of the stock options. |
| 02/19/2025 | Date of signature for the Form 4 filing. |
| 02/15/2026 | First vesting date (25%) of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.